Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis (Confors)

Medical University of Vienna

Status and phase: Completed; Phase 4

Conditions: Osteoporosis

Treatments: Drug: teriparatide; Drug: teriparatide and alendronate; Drug: teriparatide and raloxifene

Study type: Interventional

Funder types: Other

Identifiers

NCT01535027

Vinforce-003

Details and patient eligibility

About

Increased bone formation in the absence of accelerated resorption is resulting in a marked anabolic response to teriparatide (TPTD) during the early phase after treatment initiation. Months later, due to coupling mechanism, the sustained increase of bone formation and ongoing anabolic effects are accompanied by significantly increased bone resorption as well. Antiresorptives influence the balance of bone formation and resorption. Therefore the investigators aim is to investigate the effects of the addition of antiresorptives to the second half of TPTD cycle when resorption is already also markedly elevated.

Full description

We prospectively randomize 125 postmenopausal women after 9 months of TPTD treatment into three different open-label groups for another 9 months: either alendronate (ALN, 70 mg/week), raloxifene (RAL, 60 mg/day) or no medication (TPTD mono) on top of ongoing TPTD treatment.

All subjects receive daily supplementation of 1000mg calcium and 800 IU vitamin D.

Serum level of intact amino terminal propeptide of type I procollagen (PINP) and type 1 collagen cross-linked C-telopeptide (CTX) as well as DXA measurement at the spine, total hip and femoral neck BMD are evaluated at TPTD treatment initiation, at baseline of randomization to antiresorptive therapy as well as at 3 and 9 months during the combination treatment.Volumetric BMD values will be also determined.

Enrollment: 125 patients

Sex: Female

Ages: 55 to 88 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ambulatory postmenopausal women at least 55 years of age
• Patients with "unsatisfactory clinical response to previous antiresorptive therapy" according to the national reimbursement criteria of Austria (either new clinical or radiographic fragility fracture on ≥ 2 years and/or accelerated bone loss of ≥ 3.5%/year on antiresorptive treatment; discontinuation of oral antiresorptive treatment due to side-effects and substantial risk for osteoporotic fracture defined by a T-Score ≤ -2.5 or ≥ 2 clinical risk factors according to the FRAX™-algorithm)and consequently started with teriparatide treatment
• Patients treated with teriparatide (20 ug/day) currently and since 9 months for postmenopausal osteoporosis
• Lumbar spine, femoral neck, and total hip evaluable by dual energy x ray absorptiometry (DXA)
• Normal or clinically non-significant abnormal laboratory values (as defined by the investigator)
• Without language barrier, cooperative, expected to return for all follow-up procedures, and who give informed consent before entering the study and after being informed of the medications and procedures to be used in this study

Exclusion criteria

• History of bone metabolic diseases, Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption
• History of malignant neoplasms in the prior 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. If malignant neoplasm was ever diagnosed, patient must presently be free of disease
• History of nephrolithiasis or urolithiasis in the prior 2 years. Patients with any documented history of nephro- or uro-lithiasis must have had an appropriate imaging procedure within the prior 6 months, such as, an intravenous pyleogram (IVP), supine radiograph of the kidney ureter bladder, or renal ultrasound, which must document the absence of stones
• Abnormal thyroid function at any time in the prior 6 months. Patients with chronic hypothyreosis and adequate substitution therapy are permitted
• Active liver disease (liver enzymes more than three times the upper limit of normal) or clinical jaundice
• Significantly impaired renal function. This is defined as serum creatinine >1.8 mg/dL
• Treatment with bone active agent other than teriparatide in the prior 9 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

125 participants in 3 patient groups

Teriparatide

Active Comparator group

Description:

18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)

Treatment:

Drug: teriparatide

Teriparatide and Raloxifene

Active Comparator group

Description:

9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months

Treatment:

Drug: teriparatide and raloxifene

Teriparatide and Alendronate

Active Comparator group

Description:

9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months

Treatment:

Drug: teriparatide and alendronate